课题基金 / 基金详情

Epigenetic characterization and therapeutic targeting of cancers harboring dysfunctional CTCF.

Epigenetic characterization and therapeutic targeting of cancers harboring dysfunctional CTCF.
CTCF 功能失调的癌症的表观遗传学特征和治疗靶向。
批准号：
379880
负责人：
Witcher Michael
金额：
$52.94万
依托单位：
Lady Davis Institute for Medical Research (Mtl)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-03-01 至 2023-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=379880&lang=en
关键词：
Ctcf Epiegentics Oncogenes Therapeutics Transcription Tumor Suppressors

项目摘要

项目成果

Witcher Michael的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Tumor suppressor proteins act to limit the proliferation and survival of cells, thereby preventing cancer and its spread to throughout the body (known as metastasis. CTCF is a protein whose normal function is commonly disrupted in breast cancer and recent
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting changes to chromatin architecture that promote breast cancer metastasis.
Targeting changes to chromatin architecture that promote breast cancer metastasis.
Targeting changes to chromatin architecture that promote breast cancer metastasis.
Oncogenic activity of poly (ADP-ribose) polymerase.